Neuroscience-focused digital data analysis technology developer IXICO has signed two new biopharmaceutical client contracts worth a total of more than £1m.
An ongoing phase III study has been extended and this will add £900,000 to the contract value.
One study has been discontinued following an interim review of data. It will not affect revenue this year, but contracted revenues of £3.5m were expected up until 2025.
© 2020 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.